Proteon Therapeutics, Inc. (NASDAQ:PRTO)‘s stock had its “hold” rating reaffirmed by investment analysts at HC Wainwright in a report released on Wednesday. They currently have a $2.30 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 9.52% from the stock’s previous close.

Several other analysts also recently issued reports on the company. Zacks Investment Research downgraded Proteon Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 18th. Oppenheimer Holdings, Inc. reissued a “market perform” rating on shares of Proteon Therapeutics in a research note on Wednesday, August 16th. Finally, Cowen and Company reissued a “hold” rating on shares of Proteon Therapeutics in a research note on Tuesday, August 8th. Nine investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $6.30.

Proteon Therapeutics (NASDAQ PRTO) opened at $2.10 on Wednesday. Proteon Therapeutics has a 12-month low of $1.10 and a 12-month high of $11.45.

Proteon Therapeutics (NASDAQ:PRTO) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.11. analysts expect that Proteon Therapeutics will post -1.54 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at

An institutional investor recently bought a new position in Proteon Therapeutics stock. RA Capital Management LLC acquired a new position in Proteon Therapeutics, Inc. (NASDAQ:PRTO) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics comprises approximately 0.2% of RA Capital Management LLC’s portfolio, making the stock its 22nd biggest holding. RA Capital Management LLC owned 7.59% of Proteon Therapeutics as of its most recent filing with the Securities and Exchange Commission. 47.07% of the stock is currently owned by institutional investors.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Stock Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related stocks with our FREE daily email newsletter.